Though some studies have shown the utility of PTEN as a marker of survival in patients with hepatobiliary cancers [56], there is a paucity of studies specifically related to its usefulness for predicting PDA recurrence and survival. This evidence concerns the gene PTEN and Patent ductus arteriosus.